Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2024; 15(12): 2370-2375
Published online Dec 15, 2024. doi: 10.4239/wjd.v15.i12.2370
Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies
Chun-Yao Cheng, Wen-Rui Hao, Ju-Chi Liu, Tzu-Hurng Cheng
Chun-Yao Cheng, Department of Medical Education, National Taiwan University Hospital, Taipei 100225, Taiwan
Wen-Rui Hao, Ju-Chi Liu, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan
Wen-Rui Hao, Ju-Chi Liu, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404333, Taiwan
Co-first authors: Chun-Yao Cheng and Wen-Rui Hao.
Author contributions: Cheng CY and Hao WR contribute equally to this study as co-first authors; Cheng CY and Hao WR conceptualized the editorial and provided critical insights into the relevance of the study; Liu JC contributed to the analysis and interpretation of the study’s findings; Cheng TH supervised the editorial process and provided overall guidance; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404333, Taiwan. thcheng@mail.cmu.edu.tw
Received: March 11, 2024
Revised: September 27, 2024
Accepted: October 29, 2024
Published online: December 15, 2024
Processing time: 251 Days and 4.1 Hours
Core Tip

Core Tip: Teneligliptin can mitigate diabetic cardiomyopathy (DCM) by inhibiting NOD-like receptor protein 3 inflammasome activation and upregulating AMP-activated protein kinase signaling. This study provides insights into the molecular mechanisms underlying the beneficial effects of teneligliptin for the treatment of DCM.